ICVX — Icosavax Income Statement
0.000.00%
Last trade - 00:00- $766.88m
- $537.68m
- $0.58m
- 37
- 21
- 78
- 42
Annual income statement for Icosavax, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 1.62 | 7.8 | 0.582 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 5.4 | 20.3 | 74.4 | 95.6 |
| Operating Profit | -5.4 | -18.7 | -66.6 | -95.1 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -5.3 | -18.9 | -67 | -91.8 |
| Net Income After Taxes | -5.3 | -18.9 | -67 | -91.8 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -5.3 | -18.9 | -67 | -91.8 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -5.97 | -18.9 | -67 | -91.8 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.159 | -0.503 | -3.69 | -2.31 |
| Dividends per Share |